Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention

Results from the OLIVUS trial

Toru Miyoshi, Atsushi Hirohata, Shinichi Usui, Keizo Yamamoto, Takashi Murakami, Issei Komatsubara, Shozo Kusachi, Tohru Ohe, Kazufumi Nakamura, Hiroshi Itoh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The OLmesartan on the progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound (OLIVUS) trial demonstrated that an angiotensin II receptor blocker, olmesartan, reduces the rate of coronary atheroma progression as evaluated by intravascular ultrasound in patients with stable angina pectoris undergoing percutaneous coronary intervention. This substudy examined the impact of olmesartan on serum biomarkers and the relationship between biomarker changes and atheroma progression. Patients in the OLIVUS trial (n = 247) were randomly assigned to a control group or the olmesartan group. A subgroup of these patients (n = 135, 55 %) was analyzed at baseline and at 14 months. Patients' characteristics and blood-pressure control were identical between the control group (n = 65) and the olmesartan group (n = 70), and also between the subpopulation and total population. The change in the level of high-sensitivity C-reactive protein (hs-CRP) (mg/l) and adiponectin (μg/ml) was significantly greater in the olmesartan group than in the control group (between-group differences: 0.5 and -0.7; 95 % confidence interval: 0.2-0.8 and -1.3 to -0.1; P = 0.001 and 0.02, respectively). Multiple regression analysis revealed that the nominal changes in total atheroma volume and percent atheroma volume were significantly associated with the nominal change in hs-CRP in the olmesartan group but not in the control group. Olmesartan reduced hs-CRP in patients with stable angina, and this correlated with the change in coronary atheroma.

Original languageEnglish
Pages (from-to)178-185
Number of pages8
JournalHeart and Vessels
Volume29
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Percutaneous Coronary Intervention
Coronary Artery Disease
Biomarkers
Atherosclerotic Plaques
C-Reactive Protein
Control Groups
Stable Angina
olmesartan
Angiotensin Receptor Antagonists
Adiponectin
Regression Analysis
Confidence Intervals
Blood Pressure
Serum
Population

Keywords

  • Angiotensin II receptor blocker
  • Coronary artery disease
  • Inflammation
  • Olmesartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention : Results from the OLIVUS trial. / Miyoshi, Toru; Hirohata, Atsushi; Usui, Shinichi; Yamamoto, Keizo; Murakami, Takashi; Komatsubara, Issei; Kusachi, Shozo; Ohe, Tohru; Nakamura, Kazufumi; Itoh, Hiroshi.

In: Heart and Vessels, Vol. 29, No. 2, 2014, p. 178-185.

Research output: Contribution to journalArticle

@article{f30797bbe0174f488b61ad73210a3905,
title = "Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: Results from the OLIVUS trial",
abstract = "The OLmesartan on the progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound (OLIVUS) trial demonstrated that an angiotensin II receptor blocker, olmesartan, reduces the rate of coronary atheroma progression as evaluated by intravascular ultrasound in patients with stable angina pectoris undergoing percutaneous coronary intervention. This substudy examined the impact of olmesartan on serum biomarkers and the relationship between biomarker changes and atheroma progression. Patients in the OLIVUS trial (n = 247) were randomly assigned to a control group or the olmesartan group. A subgroup of these patients (n = 135, 55 {\%}) was analyzed at baseline and at 14 months. Patients' characteristics and blood-pressure control were identical between the control group (n = 65) and the olmesartan group (n = 70), and also between the subpopulation and total population. The change in the level of high-sensitivity C-reactive protein (hs-CRP) (mg/l) and adiponectin (μg/ml) was significantly greater in the olmesartan group than in the control group (between-group differences: 0.5 and -0.7; 95 {\%} confidence interval: 0.2-0.8 and -1.3 to -0.1; P = 0.001 and 0.02, respectively). Multiple regression analysis revealed that the nominal changes in total atheroma volume and percent atheroma volume were significantly associated with the nominal change in hs-CRP in the olmesartan group but not in the control group. Olmesartan reduced hs-CRP in patients with stable angina, and this correlated with the change in coronary atheroma.",
keywords = "Angiotensin II receptor blocker, Coronary artery disease, Inflammation, Olmesartan",
author = "Toru Miyoshi and Atsushi Hirohata and Shinichi Usui and Keizo Yamamoto and Takashi Murakami and Issei Komatsubara and Shozo Kusachi and Tohru Ohe and Kazufumi Nakamura and Hiroshi Itoh",
year = "2014",
doi = "10.1007/s00380-013-0343-0",
language = "English",
volume = "29",
pages = "178--185",
journal = "Heart and Vessels",
issn = "0910-8327",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention

T2 - Results from the OLIVUS trial

AU - Miyoshi, Toru

AU - Hirohata, Atsushi

AU - Usui, Shinichi

AU - Yamamoto, Keizo

AU - Murakami, Takashi

AU - Komatsubara, Issei

AU - Kusachi, Shozo

AU - Ohe, Tohru

AU - Nakamura, Kazufumi

AU - Itoh, Hiroshi

PY - 2014

Y1 - 2014

N2 - The OLmesartan on the progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound (OLIVUS) trial demonstrated that an angiotensin II receptor blocker, olmesartan, reduces the rate of coronary atheroma progression as evaluated by intravascular ultrasound in patients with stable angina pectoris undergoing percutaneous coronary intervention. This substudy examined the impact of olmesartan on serum biomarkers and the relationship between biomarker changes and atheroma progression. Patients in the OLIVUS trial (n = 247) were randomly assigned to a control group or the olmesartan group. A subgroup of these patients (n = 135, 55 %) was analyzed at baseline and at 14 months. Patients' characteristics and blood-pressure control were identical between the control group (n = 65) and the olmesartan group (n = 70), and also between the subpopulation and total population. The change in the level of high-sensitivity C-reactive protein (hs-CRP) (mg/l) and adiponectin (μg/ml) was significantly greater in the olmesartan group than in the control group (between-group differences: 0.5 and -0.7; 95 % confidence interval: 0.2-0.8 and -1.3 to -0.1; P = 0.001 and 0.02, respectively). Multiple regression analysis revealed that the nominal changes in total atheroma volume and percent atheroma volume were significantly associated with the nominal change in hs-CRP in the olmesartan group but not in the control group. Olmesartan reduced hs-CRP in patients with stable angina, and this correlated with the change in coronary atheroma.

AB - The OLmesartan on the progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound (OLIVUS) trial demonstrated that an angiotensin II receptor blocker, olmesartan, reduces the rate of coronary atheroma progression as evaluated by intravascular ultrasound in patients with stable angina pectoris undergoing percutaneous coronary intervention. This substudy examined the impact of olmesartan on serum biomarkers and the relationship between biomarker changes and atheroma progression. Patients in the OLIVUS trial (n = 247) were randomly assigned to a control group or the olmesartan group. A subgroup of these patients (n = 135, 55 %) was analyzed at baseline and at 14 months. Patients' characteristics and blood-pressure control were identical between the control group (n = 65) and the olmesartan group (n = 70), and also between the subpopulation and total population. The change in the level of high-sensitivity C-reactive protein (hs-CRP) (mg/l) and adiponectin (μg/ml) was significantly greater in the olmesartan group than in the control group (between-group differences: 0.5 and -0.7; 95 % confidence interval: 0.2-0.8 and -1.3 to -0.1; P = 0.001 and 0.02, respectively). Multiple regression analysis revealed that the nominal changes in total atheroma volume and percent atheroma volume were significantly associated with the nominal change in hs-CRP in the olmesartan group but not in the control group. Olmesartan reduced hs-CRP in patients with stable angina, and this correlated with the change in coronary atheroma.

KW - Angiotensin II receptor blocker

KW - Coronary artery disease

KW - Inflammation

KW - Olmesartan

UR - http://www.scopus.com/inward/record.url?scp=84897020719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897020719&partnerID=8YFLogxK

U2 - 10.1007/s00380-013-0343-0

DO - 10.1007/s00380-013-0343-0

M3 - Article

VL - 29

SP - 178

EP - 185

JO - Heart and Vessels

JF - Heart and Vessels

SN - 0910-8327

IS - 2

ER -